Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression

NCT03228394 is registered in ClinicalTrials.gov with Marinus Pharmaceuticals as lead sponsor.

NCT NCT03228394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03228394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression
Lead sponsor
Marinus Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 27, 2017
Completion date
May 10, 2020
Enrollment
91 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

behavioral symptoms, depression, depression, postpartum, depressive disorder, mental disorders, mood disorders, postpartum, ppd, pregnancy complications, puerperal disorders